Details

Autor(en) / Beteiligte

• Hessey, Sonya
• Huebner, Ariana
• Pich, Oriol
• Bunkum, Abi
• Liu, Wing
• Moore, David A.
• Naceur-Lombardelli, Cristina
• Veeriah, Selvaraju
• Ward, Sophie
• Salgado, Roberto
• McGranahan, Nicholas
• Zaccaria, Simone
• Swanton, Charles
• Jamal-Hanjani, Mariam

Titel

Abstract 2037: Tracking the emergence of immunotherapy resistance in lung cancer metastases

Ist Teil von

• Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2037-2037

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• Abstract Metastatic non-small cell lung cancer (NSCLC) results from a complex evolutionary process in which cancer cells migrate from a primary tumour to a new anatomical site. Immunotherapy is frequently used to treat NSCLC, but drug resistance is frequent (>50%) and metastasis remains the most common cause of death. Recent studies of primary and metastatic tumours suggest that anti-cancer treatments can impact cancer evolutionary dynamics by applying selective pressures that promote the development of treatment resistance in genetically distinct subpopulations of cancer cells, or tumour clones. However, the relationship between metastatic progression and the development of resistance to immunotherapy has not been fully explored. In particular, whether metastases become resistant to immunotherapy as a result of the migration of resistant cells or whether distinct metastatic sites converge in parallel toward an immunotherapy resistance phenotype irrespective of cell migration, is not known. In this work, we investigate the role of metastatic cell migration in the development of immunotherapy resistance using DNA sequencing data from primary and metastatic tumour samples from twelve immunotherapy-treated patients with NSCLC co-recruited to the national TRACERx and PEACE studies. Using computational approaches, we identified distinct tumour clones in primary and metastatic tumours and used these to reconstruct tumour phylogenies for each patient. By evaluating tumour clonal dynamics in relation to treatment, we classified tumour clones as either sensitive or resistant to immunotherapy. We reconstructed the metastatic migration histories of these clones using existing computational methods based on somatic single nucleotide variants. Our results suggest that heterogeneous mechanisms of immune evasion develop in parallel at distinct metastatic sites. The ongoing analysis of the genetic changes that distinguish resistant from sensitive clones, and migrating from non-migrating clones, will provide further detail regarding the impact of metastatic migrations on immunotherapy resistance. Using this approach to map the evolutionary history of metastatic NSCLC, we provide insight into the mechanism by which immunotherapy resistance develops at distinct metastatic sites. Citation Format: Sonya Hessey, Ariana Huebner, Oriol Pich, Abi Bunkum, Wing Liu, David A. Moore, Cristina Naceur-Lombardelli, Selvaraju Veeriah, Sophie Ward, Roberto Salgado, Nicholas McGranahan, Simone Zaccaria, Charles Swanton, Mariam Jamal-Hanjani. Tracking the emergence of immunotherapy resistance in lung cancer metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2037.